CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 11 enrolled / 11 target
Drug / intervention
CLS12311 low +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06430671
NCT06430671Phase 1CompletedUpdate Overdue (0.5/mo)Completion was 6mo ago
CompareCT.gov

Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients With Relapsing Remitting Multiple Sclerosis - RED4MS Trial

Cellerys AG·interventional·Posted May 28, 2024·Updated Jun 8, 2026

In Brief

A Phase 1 clinical trial evaluating CLS12311 low, CLS12311 medium, and 2 other interventions for Relapsing-remitting Multiple Sclerosis (RRMS). Completed, enrolled 11 participants across 8 sites in 4 countries.

Signals

Enrollment appears stalled

Detailed Summary

RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-remitting Multiple Sclerosis (RRMS)
CountriesCzechia, Germany, Italy, Switzerland
CollaboratorsNovartis, Scope International AG, Tetec AG, Jung Diagnostics GmbH

Timeline

Phase 1CompletedFinished
20252026
First PostedMay 28, 2024
Enrollment StartJun 18, 2024
Primary CompletionDec 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 2.1 years ago

Arms & Interventions

CLS12311 lowexperimental

Low dose CLS12311

Drug: CLS12311 lowDrug: uncoupled RBCs
CLS12311 mediumexperimental

Medium dose CLS12311

Drug: CLS12311 mediumDrug: uncoupled RBCs
CLS12311 highexperimental

High dose CLS12311

Drug: CLS12311 high

Interventions

CLS12311 lowdrug

Peptide-coupled Red Blood Cells (RBCs)

CLS12311 mediumdrug

Peptide-coupled Red Blood Cells (RBCs)

CLS12311 highdrug

Peptide-coupled Red Blood Cells (RBCs)

uncoupled RBCsdrug

autologous Red Blood Cells (RBCs)